Literature DB >> 21889719

Androgens and breast cancer in men and women.

Constantine Dimitrakakis1.   

Abstract

Abundant clinical evidence suggests that androgens normally inhibit mammary epithelial proliferation and breast growth. Clinical and nonhuman primate studies support the notion that androgens inhibit mammary proliferation and, thus, may protect from breast cancer. On the other hand, administration of conventional estrogen treatment suppresses endogenous androgens and may, thus, enhance estrogenic breast stimulation and possibly breast cancer risk. Addition of testosterone to the usual hormone therapy regimen may diminish the estrogen/progestin increase in breast cancer risk, but the impact of this combined use on mammary gland homeostasis still needs evaluation.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21889719     DOI: 10.1016/j.ecl.2011.05.007

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  8 in total

1.  Dietary lignan intake and androgen receptor expression in breast tumors.

Authors:  AnnaLynn M Williams; Matthew Bonner; Heather M Ochs-Balcom; Helena Hwang; Carl Morrison; Susan E McCann
Journal:  Cancer Causes Control       Date:  2014-12-04       Impact factor: 2.506

2.  Breast Cancer Incidence Reduction in Women Treated with Subcutaneous Testosterone: Testosterone Therapy and Breast Cancer Incidence Study.

Authors:  Gary Donovitz; Mandy Cotten
Journal:  Eur J Breast Health       Date:  2021-03-31

Review 3.  Benefits and risks of testosterone treatment for hypoactive sexual desire disorder in women: a critical review of studies published in the decades preceding and succeeding the advent of phosphodiesterase type 5 inhibitors.

Authors:  Sandra Léa Bonfim Reis; Carmita H N Abdo
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

4.  Subcutaneous testosterone-letrozole therapy before and concurrent with neoadjuvant breast chemotherapy: clinical response and therapeutic implications.

Authors:  Rebecca L Glaser; Anne E York; Constantine Dimitrakakis
Journal:  Menopause       Date:  2017-07       Impact factor: 2.953

5.  Rapid response of breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: neoadjuvant hormone therapy in breast cancer.

Authors:  Rebecca L Glaser; Constantine Dimitrakakis
Journal:  Menopause       Date:  2014-06       Impact factor: 2.953

6.  Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study.

Authors:  Rebecca L Glaser; Anne E York; Constantine Dimitrakakis
Journal:  BMC Cancer       Date:  2019-12-30       Impact factor: 4.430

7.  Establishing a Cohort of Transgender Men and Gender Nonconforming Individuals to Understand the Molecular Impact of Testosterone on Breast Physiology.

Authors:  Gabrielle M Baker; Michael E Pyle; Adam M Tobias; Richard A Bartlett; Jordana Phillips; Valerie J Fein-Zachary; Gerburg M Wulf; Yujing J Heng
Journal:  Transgend Health       Date:  2019-11-19

Review 8.  Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms.

Authors:  Christine M Friedenreich; Charlotte Ryder-Burbidge; Jessica McNeil
Journal:  Mol Oncol       Date:  2020-08-18       Impact factor: 6.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.